Novo Nordisk uses AI to fast-track drug launches, expand India role

Novo Nordisk is aiming to slash the time it takes to bring new drugs to market by up to two-thirds using AI, a top executive said, as the Danish drugmaker looks to regain momentum in the booming obesity drugs market.

“Historically, from ‘last patient, last visit’ to first filing might have been a year and a half. What we’re ‌able to do ⁠now by ⁠implementing AI is bring that time down by months,” John Dawber, managing director for global business services, told a Reuters summit on Friday.